← Back to Clinical Trials
Recruiting NCT06802939

NCT06802939 RTMS for Refractory Auditory Hallucinations Based on Personalized Targets Using Magnetoencephalography

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06802939
Status Recruiting
Phase
Sponsor Shanghai Mental Health Center
Condition Refractory Auditory Hallucinations
Study Type INTERVENTIONAL
Enrollment 36 participants
Start Date 2025-02-05
Primary Completion 2026-12-10

Eligibility & Interventions

Sex All sexes
Min Age 13 Years
Max Age 55 Years
Study Type INTERVENTIONAL
Interventions
rTMS

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 36 participants in total. It began in 2025-02-05 with a primary completion date of 2026-12-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is an before-after study in the same patient, which enrolled 36 psychiatric patients with refractory auditory hallucinations. The target of patient intervention relies on the results of magnetoencephalography localization. The medication and dosage remain unchanged during the intervention period. The investigators assume that the intervention targets for each auditory hallucination patient are individualized.

Eligibility Criteria

Inclusion Criteria: * Clinical diagnosis of schizophrenia * Must be able to right-handed * Primary school education or above * Understand and sign a written informed consent form (jointly signed by the guardian and the participant if under 18 years old) * Existence of persistent auditory hallucinations (defined as: taking sufficient antipsychotic medication for at least 6 months, combined with 3 antipsychotic medications still ineffective, and no significant improvement in auditory hallucinations symptoms, with an AHRS score still\>12) Exclusion Criteria: * MECT treatment within the past 3 months * Major physical illnesses (organic lesions such as sensory and motor disorders, neurological disorders, and traumatic brain injury) * Taboo symptoms for rTMS treatment (such as intracranial metal implants) * Aggressive behavior and an impulse to damage equipment * Metal (including orthodontic treatment, dental implants) and tattoos inside the body * Claustrophobia

Contact & Investigator

Central Contact

Yegang Hu, Doctor

✉ yeganghu@126.com

📞 +86-21-52219305

Frequently Asked Questions

Who can join the NCT06802939 clinical trial?

This trial is open to participants of all sexes, aged 13 Years or older, up to 55 Years, studying Refractory Auditory Hallucinations. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06802939 currently recruiting?

Yes, NCT06802939 is actively recruiting participants. Contact the research team at yeganghu@126.com for enrollment information.

Where is the NCT06802939 trial being conducted?

This trial is being conducted at Shanghai, China.

Who is sponsoring the NCT06802939 clinical trial?

NCT06802939 is sponsored by Shanghai Mental Health Center. The trial plans to enroll 36 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology